XNCR catalyst calendar

Xencor Inc

Upcoming catalysts
8
Cash runway
2 months
Cash & investments
$45M

Xencor Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on December 11, 2026, a projected date rather than a confirmed one. There are 8 upcoming events on record.

Cash runway is approximately 2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 22 concluded trials, 73% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 11, 2026 est. Next quarterly earnings (projected) Earnings —
February 15, 2027 Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Trial Milestone Phase 1
May 15, 2027 Study of XmAb412 in Healthy Participants Trial Milestone Phase 1
December 15, 2027 Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis Trial Milestone Phase 1/Phase 2
December 15, 2027 Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors Trial Milestone Phase 1
June 15, 2028 A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis Trial Milestone Phase 1
October 15, 2028 A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases Trial Milestone Phase 1
December 15, 2028 Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors Trial Milestone Phase 1

Track XNCR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open XNCR in the tracker

Recent history

DateEventTypePhase
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 29, 2026 Quarterly results filed (8-K) Earnings —
May 6, 2026 Quarterly results filed (8-K) Earnings —
May 5, 2026 8-K filed: Reg FD disclosure Filing —
April 27, 2026 8-K filed: Leadership change Corporate —
March 4, 2026 8-K filed: Reg FD disclosure Filing —
February 25, 2026 Quarterly results filed (8-K) Earnings —
January 8, 2026 Quarterly results filed (8-K) Earnings —
December 24, 2025 Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC Trial Milestone Phase 1/Phase 2
November 5, 2025 Quarterly results filed (8-K) Earnings —
October 24, 2025 8-K filed: Reg FD disclosure Filing —
October 15, 2025 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Trial Milestone Phase 2
August 6, 2025 Quarterly results filed (8-K) Earnings —
July 31, 2025 8-K filed: Leadership change Corporate —
June 10, 2025 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Trial Milestone Phase 2
May 20, 2025 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors Trial Milestone Phase 1
May 7, 2025 Quarterly results filed (8-K) Earnings —
April 30, 2025 8-K filed: Reg FD disclosure Filing —
May 21, 2024 A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors Trial Milestone Phase 1
April 15, 2024 Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies Trial Milestone Phase 1
March 22, 2024 Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis Trial Milestone Phase 1
February 15, 2024 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Trial Milestone Phase 1
February 21, 2023 Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Trial Milestone Phase 2
February 16, 2023 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Trial Milestone Phase 1
November 10, 2022 Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers Trial Milestone Phase 1
June 1, 2022 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Trial Milestone Phase 1
March 24, 2022 Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer Trial Milestone Phase 1/Phase 2
October 26, 2021 A Study of XmAb®18087 in Subjects With NET and GIST Trial Milestone Phase 1
September 15, 2021 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Trial Milestone Phase 1
June 19, 2020 Study Evaluating AMG 424 in Subjects With Multiple Myeloma Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.